FindTrial
Sign In

Empagliflozin Tablets

DRUG7 trials

Sponsors

Jing'an District Hospital of Traditional Chinese Medicine (TCM), Chia Tai Tianqing Pharmaceutical Group Co., Ltd., Kobe University, Yaounde Central Hospital, Centre Hospitalier Universitaire Vaudois

Conditions

DMD-associated Dilated CardiomyopathyHeart FailureHypertensionInsulin Resistance - Type AInsulin Resistance - Type BInsulin Resistance SyndromeLipoatrophic Diabetes MellitusType 2 Diabetes

Early Phase 1

To evaluate the clinical randomized controlled study of warming acupuncture combined with Western medicine in the treatment of chronic heart failure with Yang deficiency and blood stasis and observe its effect on inflammatory factors
RecruitingChiCTR2300078508
Jing'an District Hospital of Traditional Chinese Medicine (TCM)chronic heart failure
Start: 2023-12-11Updated: 2023-12-19

Phase 2

Repurposing Empagliflozin and Dapagliflozin for Paediatric Heart Failure: Translational Approach and Dose Rationale
Not yet recruitingNCT06012266
Centre Hospitalier Universitaire VaudoisHeart Failure
Start: 2024-08-31End: 2025-08-31Target: 12Updated: 2024-02-07
Repurposing Empagliflozin for DMD-associated Cardiomyopathy in Children 6-18 Years of Age
Not yet recruitingNCT06643442
Sebastiano LavaDMD-associated Dilated Cardiomyopathy
Start: 2025-10-01End: 2027-03-31Target: 12Updated: 2025-08-15

Phase 3

A Study of Empagliflozin in Patients With Refractory Diabetes Mellitus With Insulin Resistance
NCT04018365
Kobe UniversityInsulin Resistance Syndrome, Insulin Resistance - Type A, Insulin Resistance - Type B +1
Start: 2019-09-01End: 2021-10-30Updated: 2021-03-03
A Extension Study of Empagliflozin in Patients With Refractory Diabetes Mellitus With Insulin Resistance ( EMPIRE-02 )
NCT04221152
Kobe UniversityInsulin Resistance Syndrome, Insulin Resistance - Type A, Insulin Resistance - Type B +1
Start: 2020-02-01End: 2022-05-31Updated: 2021-06-03

Phase 4

Short Term Effect of Empagliflozin in Hypertension
CompletedNCT04203914
Yaounde Central HospitalHypertension
Start: 2017-01-10End: 2017-09-30Updated: 2019-12-23

Unknown Phase

Bioequivalence Study of Empagliflozin Tablet in Healthy Participants.
CompletedNCT03771781
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.Type 2 Diabetes
Start: 2018-04-16End: 2018-05-25Updated: 2019-02-21

Related Papers

A Multicenter, Open-Label, Single-Arm Trial of the Efficacy and Safety of Empagliflozin Treatment for Refractory Diabetes Mellitus with Insulin Resistance (EMPIRE-01)
Diabetes Therapy2024-01-137 citations
A Qualitative Research Study of Experiences and Perceptions of People Living with Insulin Resistance Syndrome or Lipoatrophic Diabetes in Japan.
2023-06-082 citations
Short Term Use of Empagliflozin Does Not Improve Left Ventricular Function in Non-Diabetic Hypertensive Patients: Results from a Non-Randomised Controlled Trial
World Journal of Cardiovascular Diseases2020-01-01